Investigating Esketamine in Adolescent Depression: Urgent Clinical Need

Major depressive disorder represents one of the most debilitating psychiatric conditions confronting pediatric populations worldwide. Consequently, adolescent patients face heightened vulnerabilities toward functional decline, self-harm, and acute suicidal crises. Standard oral antidepressants typically require four to six weeks to manifest meaningful clinical responses. Therefore, treating clinicians encounter a precarious therapeutic gap when managing adolescents in severe psychiatric distress. The rigorous investigation of esketamine in adolescent depression addresses this profound unmet need. Esketamine, an S-enantiomer of ketamine, functions primarily as an N-methyl-D-aspartate receptor antagonist to stimulate rapid synaptic neuroplasticity. While international regulatory authorities approved esketamine nasal spray for adults experiencing treatment-resistant depression or acute suicidal thoughts, pediatric data remained scarce. Adolescents at imminent risk of suicide are routinely excluded from randomized clinical trials due to heightened safety concerns. Consequently, child and adolescent psychiatrists have lacked high-quality evidence to guide rapid-acting pharmacotherapy during acute crises. To resolve this critical evidence gap, researchers conducted a double-blind, psychoactive-controlled phase 2b trial. This study evaluated whether intranasal esketamine could rapidly alleviate depressive symptoms within hours, establishing essential benchmarks for youth psychiatric crisis management.

Trial Design and Psychoactive Comparator Methodology

The phase 2b clinical trial enrolled 147 adolescents aged 12 to 17 years across multinational medical sites. Crucially, every participant met formal diagnostic criteria for major depressive disorder and presented at imminent risk for suicide requiring acute hospitalization. Investigators implemented a randomized, double-blind, double-dummy study design. They allocated patients in a 1:1:1:2 ratio to receive intranasal esketamine at 28 mg, 56 mg, or 84 mg, or an active psychoactive placebo of oral midazolam twice weekly for four weeks. Researchers intentionally selected midazolam as the comparator because it induces transient sedation and light sensory alterations. Consequently, this choice mitigated potential unblinding caused by ketamine-induced dissociative side effects. Additionally, all enrolled youth received comprehensive standard-of-care psychiatric interventions throughout the entire study duration. This foundational protocol included acute inpatient crisis stabilization, structured evidence-based psychotherapy, and newly initiated or optimized oral antidepressant pharmacotherapy. The primary efficacy endpoint measured change in the Children's Depression Rating Scale-Revised total score from baseline to 24 hours post-dose. Furthermore, investigators tracked clinical outcomes across a six-month follow-up window to evaluate long-term recovery and symptom trajectories.

Primary Efficacy Findings and Rapid Depressive Symptom Relief

The clinical trial met its primary efficacy endpoint, demonstrating robust symptom alleviation within twenty-four hours of treatment initiation. Specifically, the pooled higher-dose esketamine cohort, which combined the 56 mg and 84 mg treatment arms, showed clear statistical superiority over the active midazolam comparator. Twenty-four hours following the initial dose, patients receiving pooled esketamine achieved a statistically significant reduction in Children's Depression Rating Scale-Revised total scores. The least squares mean difference between groups demonstrated a substantial 5.8-point advantage favoring esketamine. However, individual dose analysis revealed varying patterns across treatment groups. While the 56 mg and 84 mg doses produced meaningful numerical improvements independently, they did not reach independent statistical significance under rigorous sequential testing procedures. Meanwhile, the lowest dose of 28 mg demonstrated limited efficacy compared with the psychoactive control. Therefore, researchers established that adequate dosing represents an essential prerequisite for rapid therapeutic response in pediatric patients. Importantly, the observed rapid relief mirrors findings previously documented in adult clinical trials. Thus, glutamatergic modulation offers immediate symptomatic reduction, providing valuable stabilization while conventional oral antidepressants gradually take effect.

Suicidality Trajectories and Crisis De-escalation Outcomes

Evaluating suicidal ideation formed a core objective of the clinical investigation. At enrollment, approximately 95% of the adolescents experienced moderate to extreme suicidal thoughts. Investigators monitored suicidality changes using the Clinical Global Impression of Severity of Suicidality-revised scale. Interestingly, suicidal thoughts improved considerably across all four study arms within the initial 24 hours. However, between-group comparisons revealed no statistically significant separation between esketamine and the active midazolam control on specific suicidality scores. Clinicians must interpret this outcome within the context of comprehensive inpatient psychiatric care. Because every participant received emergency hospitalization, continuous psychiatric nursing supervision, and intensive psychotherapy, the supportive hospital environment produced immense therapeutic benefits. Consequently, this multi-modal crisis environment drove rapid reductions in suicidal distress across both active and control cohorts. Nonetheless, reducing global depressive severity through esketamine provides critical secondary benefits during acute crises. When overwhelming depressive feelings recede rapidly, adolescents regain cognitive capacity to participate constructively in cognitive behavioral or psychodynamic psychotherapy. Therefore, rapid mood alleviation remains an essential mechanism for crisis stabilization, even when institutional safety interventions concurrently reduce explicit suicidal intent.

Safety Profile, Tolerability, and Practical Clinical Implications

Evaluating drug safety is paramount when administering novel psychiatric therapeutics in pediatric medicine. Overall, intranasal esketamine displayed a tolerability profile consistent with adult trials, although specialized youth monitoring remains indispensable. The most common adverse events included dizziness, nausea, transient dissociation, headache, dysgeusia, and somnolence. Typically, dissociative symptoms appeared shortly after inhalation and resolved spontaneously within two hours. Investigators also documented transient blood pressure elevations, which returned to baseline without requiring pharmacological treatment. Crucially, intentional self-injury and suicidal behavior occurred in a small minority of participants across all study arms. These events reflected the severe underlying psychiatric vulnerability of this acute inpatient cohort rather than drug-induced toxicity. Nonetheless, strict clinical safeguards remain imperative. Clinicians must administer esketamine exclusively within certified healthcare settings equipped with dedicated medical supervision. Furthermore, healthcare staff must observe adolescents for at least two hours following each dose to monitor cardiovascular parameters and psychiatric stability. Looking ahead, clinicians must view esketamine as an acute bridging therapy rather than a stand-alone cure. Integrating rapid glutamatergic treatment into comprehensive psychiatric programs offers genuine hope for rapidly de-escalating life-threatening depressive episodes in vulnerable youth.

How does esketamine differ from traditional antidepressants in adolescents?

Traditional oral antidepressants target monoaminergic neurotransmission and typically require four to six weeks to produce meaningful clinical improvement. In contrast, esketamine targets NMDA glutamate receptors to stimulate rapid synaptic neuroplasticity. Consequently, intranasal esketamine can significantly reduce depressive severity within 24 hours, offering vital mood stabilization during acute youth psychiatric crises.

Did esketamine significantly decrease suicidal ideation compared to midazolam?

Although depressive symptoms improved significantly with esketamine, specific suicidality scores decreased similarly across both esketamine and active control groups. Comprehensive standard care, including immediate hospitalization, crisis psychotherapy, and constant clinical monitoring, produced substantial therapeutic benefits for all adolescents, thereby narrowing measurable statistical differences between trial arms regarding suicidality alone.

What safety precautions are necessary when administering esketamine to adolescents?

Clinicians must administer esketamine exclusively within certified healthcare facilities equipped for immediate medical intervention. Patients require clinical observation for at least two hours following each dose to monitor transient blood pressure increases, sedation, and dissociative reactions. Healthcare providers must also monitor adolescents closely for emergent behavioral changes and intentional self-injury risk.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Kosik-Gonzalez C et al. Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. J Am Acad Child Adolesc Psychiatry. 2026 Jan. doi: 10.1016/j.jaac.2025.02.015. PMID: 40058488.


2. Ionescu DF, Fu DJ, Qiu X, et al. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol. 2021;24(1):22-31.


3. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Depressive Disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503-1526.